Aurelio Castrellon, MD
I am a medical oncologist with board certifications in medical oncology, hematology and internal medicine. I care for patients at Memorial Cancer Institute who are battling various stages of breast cancer.
Oncology is a rapidly changing field, where new developments and treatment options are continually being discovered. I consider it a critical part of my job to stay up-to-date on the latest findings. I am actively involved in clinical trials and research at Memorial Cancer Institute, which means our patients have access to new drugs that are not yet offered nationwide. I am proud to be making a difference in the lives of my patients and bringing us all closer to a cure.
While the technical sides of my job are crucial, I never forget that my main purpose is to help my patients during a very difficult time in their life. I want all of my patients to feel comfortable communicating with me, to know that I will listen to everything they have to say and that together we will find the right treatment options that will give them the best quality of life.
Before joining Memorial, I practiced medical oncology in New Mexico for five years. I also worked at Jackson Memorial Hospital and the University of Miami Sylvester Comprehensive Cancer Center, where I trained with world-renowned authorities in the treatment of breast cancer.
Related Medical Services
Meet Dr. Castrellon
- Universidad De Panama, 2000
- Jackson Memorial Hospital, 2006, Internal Medicine
- Jackson Memorial Hospital, 2009, Oncology
American Board of Internal Medicine-Medical Oncology
- Eric Reiss Award for Excellent Teaching Resident, Jackson Memorial Hospital, 2005
- American Society of Clinical Oncology
- American Society of Hematology
- American College of Physicians
At Memorial Cancer Institute, I am a principle investigator and participant in clinical trials and research aimed at finding new treatment options and a cure for breast cancer. These trials explore new drugs, treatment protocols and side effects of breast cancer treatment.
Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis
- SWOG S1207
Phase III Randomized, Placebo-Controlled Clinical
Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and
HER2/neu Negative Breast Cancer.
- ONT-380-206 (HER2CLIMB)
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma